Masimo Co. (NASDAQ:MASI) Shares Purchased by Xponance Inc.

Xponance Inc. boosted its position in shares of Masimo Co. (NASDAQ:MASI) by 4.4% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 7,025 shares of the medical equipment provider’s stock after acquiring an additional 299 shares during the quarter. Xponance Inc.’s holdings in Masimo were worth $1,161,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the company. Westfield Capital Management Co. LP lifted its holdings in shares of Masimo by 23.2% during the third quarter. Westfield Capital Management Co. LP now owns 1,394,056 shares of the medical equipment provider’s stock worth $185,869,000 after purchasing an additional 262,370 shares during the period. National Bank of Canada FI raised its position in Masimo by 195.6% during the 3rd quarter. National Bank of Canada FI now owns 132,500 shares of the medical equipment provider’s stock worth $17,666,000 after buying an additional 87,675 shares during the last quarter. Lecap Asset Management Ltd. acquired a new stake in Masimo during the 4th quarter valued at approximately $1,607,000. Nisa Investment Advisors LLC boosted its holdings in shares of Masimo by 16,740.0% in the 4th quarter. Nisa Investment Advisors LLC now owns 5,052 shares of the medical equipment provider’s stock valued at $835,000 after acquiring an additional 5,022 shares during the last quarter. Finally, Trust Point Inc. acquired a new stake in shares of Masimo in the fourth quarter worth $230,000. Hedge funds and other institutional investors own 85.96% of the company’s stock.

Insider Buying and Selling at Masimo

In related news, Director Craig B. Reynolds sold 2,053 shares of the company’s stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $166.13, for a total transaction of $341,064.89. Following the completion of the transaction, the director now owns 16,581 shares in the company, valued at $2,754,601.53. This represents a 11.02 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Bilal Muhsin sold 30,000 shares of Masimo stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $167.49, for a total value of $5,024,700.00. Following the completion of the sale, the chief operating officer now owns 24,172 shares in the company, valued at approximately $4,048,568.28. The trade was a 55.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 9.70% of the company’s stock.

Masimo Stock Performance

NASDAQ MASI opened at $165.82 on Monday. The stock has a market capitalization of $8.95 billion, a price-to-earnings ratio of 114.36 and a beta of 1.04. The stock has a 50-day moving average of $174.99 and a 200 day moving average of $159.82. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. Masimo Co. has a twelve month low of $101.61 and a twelve month high of $194.88.

Masimo (NASDAQ:MASI) last announced its earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.42 by $0.38. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The business had revenue of $600.70 million during the quarter, compared to the consensus estimate of $593.35 million. Sell-side analysts anticipate that Masimo Co. will post 4.1 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Raymond James upped their price target on shares of Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a report on Friday, December 27th. Wells Fargo & Company raised their target price on Masimo from $193.00 to $205.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. Piper Sandler lifted their price target on Masimo from $210.00 to $215.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. Finally, Needham & Company LLC restated a “hold” rating on shares of Masimo in a research report on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $194.80.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.